mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Chemotherapeutic agents</td><td align="center">Treatment regimens</td><td align="center">References</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Platinum-based agents (cisplatin/carboplatin)</td><td align="center">Single agent or in combination  with 5-fluorouracil or taxane  agents</td><td align="center">[<a href="/journals/isrn/2012/953089/#B5">5</a>]</td></tr><tr><td align="left">Taxane agents (docetaxel/paclitaxel)</td><td align="center">In combination with cisplatin or 5-fluorouracil</td><td align="center">[<a href="/journals/isrn/2012/953089/#B6">6</a>]</td></tr><tr><td align="left">5-Fluorouracil</td><td align="center">In combination with cisplatin or taxane agents</td><td align="center">[<a href="/journals/isrn/2012/953089/#B7">7</a>]</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Chemotherapeutic model for head and neck cancer.

International Scholarly Research Notices

tab1

Table 1

Table 1: mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer 